Epitope spreading can also undermine therapy response through the generation of anti-drug antibodies (ADA), which are reported at high frequencies in SLE patients treated with rituximab and are associated with reduced circulating drug levels and early relapse (79). The gene discussed is ADA; the disease is systemic lupus erythematosus.